On the other hand, ruxolitinib, a Janus kinase (JAK) 1 and 2 inhibitor that blocks signaling of pro-inflammatory cytokines including IFN-γ and IL-6, has been proven to be effective for the treatment of pediatric HLH (47). This evidence concerns the gene IL6 and hemophagocytic syndrome.